FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2464630776> ?p ?o ?g. }

• W2464630776 endingPage "49732" @default.
• W2464630776 startingPage "49722" @default.
• W2464630776 abstract "// Zheng Ge 1 , Yan Gu 2 , Gang Zhao 1 , Jianyong Li 2 , Baoan Chen 1 , Qi Han 2 , Xing Guo 2 , Juan Liu 2 , Hui Li 3 , Michael D. Yu 4 , Justin Olson 5 , Sadie Steffens 3 , Kimberly J. Payne 6 , Chunhua Song 3 , Sinisa Dovat 3 1 Department of Hematology, Zhongda Hospital, Medical School of Southeast University, Nanjing, 210009, China 2 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China 3 Department of Pediatrics, Pennsylvania State University Medical College, Hershey, PA, 17033, USA 4 Sydney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, 19107 USA 5 University of Wisconsin at Stout, Menomonie, WI, 54751, USA 6 Loma Linda University, Department of Pathology and Human Anatomy, Loma Linda, CA, 92350, USA Correspondence to: Zheng Ge, email: Janege879@hotmail.com Chunhua Song, email: csong@hmc.psu.edu Sinisa Dovat, email: sdovat@hmc.psu.edu Keywords: CRLF2, IKZF1, adult, acute lymphoblastic leukemia Received: June 06, 2016      Accepted: June 24, 2016      Published: July 06, 2016 ABSTRACT Overexpression of cytokine receptor-like factor 2 ( CRLF2 ) due to chromosomal rearrangement has been observed in acute lymphoblastic leukemia (ALL) and reported to contribute to oncogenesis and unfavorable outcome in ALL. We studied B-ALL and T-ALL patients without CRLF2 rearrangement and observed that CRLF2 is significantly increased in a subset of these patients. Our study shows that high CRLF2 expression correlates with high-risk ALL markers, as well as poor survival. We found that the IKZF1 -encoded protein, Ikaros, directly binds to the CRLF2 promoter and regulates CRLF2 expression in leukemia cells. CK2 inhibitor, which can increase Ikaros activity, significantly increases Ikaros binding in ALL cells and suppresses CRLF2 expression in an Ikaros-dependent manner. CRLF2 expression is significantly higher in patients with IKZF1 deletion as compared to patients without IKZF1 deletion. Treatment with CK2 inhibitor also results in an increase in IKZF1 binding to the CRLF2 promoter and suppression of CRLF2 expression in primary ALL cells. We further observed that CK2 inhibitor induces increased H3K9me 3 histone modifications in the CRLF2 promoter in ALL cell lines and primary cells. Taken together, our results demonstrate that high expression of CRLF2 correlates with high-risk ALL and short survival in patients without CRLF2 rearrangement. Our results are the first to demonstrate that the IKZF1 -encoded Ikaros protein directly suppresses CRLF2 expression through enrichment of H3K9me 3 in its promoter region. Our data also suggest that high CRLF2 expression works with the IKZF1 deletion to drive oncogenesis of ALL and has significance in an integrated prognostic model for adult high-risk ALL." @default.
• W2464630776 created "2016-07-22" @default.
• W2464630776 creator A5022730241 @default.
• W2464630776 creator A5029197578 @default.
• W2464630776 creator A5036602923 @default.
• W2464630776 creator A5037993505 @default.
• W2464630776 creator A5039204274 @default.
• W2464630776 creator A5040795427 @default.
• W2464630776 creator A5040795581 @default.
• W2464630776 creator A5053898007 @default.
• W2464630776 creator A5065859286 @default.
• W2464630776 creator A5072518893 @default.
• W2464630776 creator A5076930880 @default.
• W2464630776 creator A5077266681 @default.
• W2464630776 creator A5077299625 @default.
• W2464630776 creator A5080125836 @default.
• W2464630776 creator A5087655461 @default.
• W2464630776 date "2016-07-06" @default.
• W2464630776 modified "2023-10-15" @default.
• W2464630776 title "High <i>CRLF2</i> expression associates with <i>IKZF1</i> dysfunction in adult acute lymphoblastic leukemia without <i>CRLF2</i> rearrangement" @default.
• W2464630776 cites W1503502817 @default.
• W2464630776 cites W1569839307 @default.
• W2464630776 cites W1910656338 @default.
• W2464630776 cites W1958612540 @default.
• W2464630776 cites W1966456827 @default.
• W2464630776 cites W1968273438 @default.
• W2464630776 cites W1984684983 @default.
• W2464630776 cites W1987294127 @default.
• W2464630776 cites W1993373584 @default.
• W2464630776 cites W2000266274 @default.
• W2464630776 cites W2012114257 @default.
• W2464630776 cites W2024996887 @default.
• W2464630776 cites W2036999612 @default.
• W2464630776 cites W2037896121 @default.
• W2464630776 cites W2059520874 @default.
• W2464630776 cites W2071700698 @default.
• W2464630776 cites W2076071435 @default.
• W2464630776 cites W2090936301 @default.
• W2464630776 cites W2093332212 @default.
• W2464630776 cites W2093996012 @default.
• W2464630776 cites W2113610514 @default.
• W2464630776 cites W2148202982 @default.
• W2464630776 cites W2151792515 @default.
• W2464630776 cites W2163001955 @default.
• W2464630776 cites W2194616187 @default.
• W2464630776 cites W2214266235 @default.
• W2464630776 cites W2273578071 @default.
• W2464630776 cites W353987122 @default.
• W2464630776 doi "https://doi.org/10.18632/oncotarget.10437" @default.
• W2464630776 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5226542" @default.
• W2464630776 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27391346" @default.
• W2464630776 hasPublicationYear "2016" @default.
• W2464630776 type Work @default.
• W2464630776 sameAs 2464630776 @default.
• W2464630776 citedByCount "33" @default.
• W2464630776 countsByYear W24646307762016 @default.
• W2464630776 countsByYear W24646307762017 @default.
• W2464630776 countsByYear W24646307762018 @default.
• W2464630776 countsByYear W24646307762019 @default.
• W2464630776 countsByYear W24646307762020 @default.
• W2464630776 countsByYear W24646307762021 @default.
• W2464630776 countsByYear W24646307762022 @default.
• W2464630776 countsByYear W24646307762023 @default.
• W2464630776 crossrefType "journal-article" @default.
• W2464630776 hasAuthorship W2464630776A5022730241 @default.
• W2464630776 hasAuthorship W2464630776A5029197578 @default.
• W2464630776 hasAuthorship W2464630776A5036602923 @default.
• W2464630776 hasAuthorship W2464630776A5037993505 @default.
• W2464630776 hasAuthorship W2464630776A5039204274 @default.
• W2464630776 hasAuthorship W2464630776A5040795427 @default.
• W2464630776 hasAuthorship W2464630776A5040795581 @default.
• W2464630776 hasAuthorship W2464630776A5053898007 @default.
• W2464630776 hasAuthorship W2464630776A5065859286 @default.
• W2464630776 hasAuthorship W2464630776A5072518893 @default.
• W2464630776 hasAuthorship W2464630776A5076930880 @default.
• W2464630776 hasAuthorship W2464630776A5077266681 @default.
• W2464630776 hasAuthorship W2464630776A5077299625 @default.
• W2464630776 hasAuthorship W2464630776A5080125836 @default.
• W2464630776 hasAuthorship W2464630776A5087655461 @default.
• W2464630776 hasBestOaLocation W24646307761 @default.
• W2464630776 hasConcept C126322002 @default.
• W2464630776 hasConcept C143998085 @default.
• W2464630776 hasConcept C194409129 @default.
• W2464630776 hasConcept C2778461978 @default.
• W2464630776 hasConcept C2909962599 @default.
• W2464630776 hasConcept C71924100 @default.
• W2464630776 hasConceptScore W2464630776C126322002 @default.
• W2464630776 hasConceptScore W2464630776C143998085 @default.
• W2464630776 hasConceptScore W2464630776C194409129 @default.
• W2464630776 hasConceptScore W2464630776C2778461978 @default.
• W2464630776 hasConceptScore W2464630776C2909962599 @default.
• W2464630776 hasConceptScore W2464630776C71924100 @default.
• W2464630776 hasIssue "31" @default.
• W2464630776 hasLocation W24646307761 @default.
• W2464630776 hasLocation W24646307762 @default.
• W2464630776 hasLocation W24646307763 @default.
• W2464630776 hasLocation W24646307764 @default.
• W2464630776 hasLocation W24646307765 @default.

• next